C
Charles Chuah
Researcher at Singapore General Hospital
Publications - 140
Citations - 8457
Charles Chuah is an academic researcher from Singapore General Hospital. The author has contributed to research in topics: Ponatinib & Myeloid leukemia. The author has an hindex of 36, co-authored 129 publications receiving 7183 citations. Previous affiliations of Charles Chuah include Imperial College London & National University of Singapore.
Papers
More filters
Journal ArticleDOI
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Hagop M. Kantarjian,Neil P. Shah,Andreas Hochhaus,Jorge E. Cortes,Sandip Shah,Manuel Ayala,Beatriz Moiraghi,Zhixiang Shen,Jiri Mayer,Ricardo Pasquini,Hirohisa Nakamae,Françoise Huguet,Concepción Boqué,Charles Chuah,Eric Bleickardt,M. Brigid Bradley-Garelik,Chao Zhu,Ted Szatrowski,David Shapiro,Michele Baccarani +19 more
TL;DR: Since achieving complete cytogenetic response within 12 months has been associated with better long-term, progression-free survival, dasatinib may improve the long- term outcomes among patients with newly diagnosed chronic-phase CML.
Journal ArticleDOI
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Jorge E. Cortes,Dong-Kee Kim,Javier Pinilla-Ibarz,P. le Coutre,Ronald Paquette,Charles Chuah,F. E. Nicolini,Jane F. Apperley,Hanna Jean Khoury,Moshe Talpaz,John F. DiPersio,Daniel J. DeAngelo,Elisabetta Abruzzese,Delphine Rea,Michele Baccarani,Martin C. Müller,Carlo Gambacorti-Passerini,Stephane Wong,Stephanie Lustgarten,Victor M. Rivera,Timothy P. Clackson,Christopher D. Turner,Frank G. Haluska,François Guilhot,Michael W. Deininger,Andreas Hochhaus,Timothy P. Hughes,J. M. Goldman,Neil P. Shah,Hagop M. Kantarjian +29 more
TL;DR: Ponatinib had significant antileukemic activity across categories of disease stage and mutation status and were durable; the estimated rate of a sustained major cytogenetic response of at least 12 months was 91%.
Journal ArticleDOI
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes,Giuseppe Saglio,Hagop M Kantarjian,Michele Baccarani,Jiří Mayer,Concepción Boqué,Neil P. Shah,Charles Chuah,Luis Casanova,Brigid Bradley-Garelik,George Manos,Andreas Hochhaus +11 more
TL;DR: These final results from the DASISION trial continue to support dasatinib 100 mg once daily as a safe and effective first-line therapy for the long-term treatment of CML-CP.
Journal ArticleDOI
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
King Pan Ng,Axel M. Hillmer,Charles Chuah,Charles Chuah,Wen Chun Juan,Tun Kiat Ko,Audrey S.M. Teo,Pramila N. Ariyaratne,Naoto Takahashi,Kenichi Sawada,Yao Fei,Yao Fei,Sheila Soh,Wah Heng Lee,John W.J. Huang,John Carson Allen,Xing Yi Woo,Niranjan Nagarajan,Vikrant Kumar,Anbupalam Thalamuthu,Wan Ting Poh,Ai Leen Ang,Hae Tha Mya,Gee Fung How,L.Y. Yang,Liang Piu Koh,Balram Chowbay,Chia-Tien Chang,V. S. Nadarajan,Wee Joo Chng,Hein Than,Lay Cheng Lim,Yeow Tee Goh,Shenli Zhang,Dianne Poh,Patrick Tan,Patrick Tan,Ju Ee Seet,Mei-Kim Ang,Noan-Minh Chau,Quan Sing Ng,Daniel Shao-Weng Tan,Manabu Soda,Kazutoshi Isobe,Markus M. Nöthen,Tien Yin Wong,Atif Shahab,Xiaoan Ruan,Valere Cacheux-Rataboul,Wing-Kin Sung,Eng Huat Tan,Yasushi Yatabe,Hiroyuki Mano,Hiroyuki Mano,Ross A. Soo,Tan Min Chin,Wan-Teck Lim,Yijun Ruan,Yijun Ruan,S. Tiong Ong +59 more
TL;DR: The results offer an explanation for the heterogeneity of TKI responses across individuals and suggest the possibility of personalizing therapy with BH3 mimetics to overcome BIM-polymorphism–associated TKI resistance.
Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-Naïve chronic myeloid leukemia patients trial
Hagop M. Kantarjian,Jorge E. Cortes,George Manos,Neil P. Shah,Jiří Mayer,Andreas Hochhaus,Michele Baccarani,Brigid Bradley Garelik,Charles Chuah,Concepción Boqué,Giuseppe Saglio,Luis Casanova Márquez +11 more